陈倩 李碧慧 康马飞

    [摘要] 在本报道中，2例晚期口腔腺癌患者化疗后进展，改用安罗替尼治疗，肿瘤有缩小(疗效评价为SD)。病例1于安罗替尼治疗后2.8个月出现耐药，肿瘤进展，给予PD-1抑制剂(特瑞普利单抗)治疗1个周期，后再次使用安罗替尼治疗，肿瘤再次缩小(疗效评价为SD)，目前仍然在维持治疗中。安罗替尼治疗的第1次无进展生存时间(PFS1)为2.8个月，第2次无进展生存时间(PFS2)为12.8+个月。病例2于安罗替尼治疗后15.5个月出现耐药，肿瘤进展，给予PD-1抑制剂(卡瑞利珠单抗)治疗4个周期，后再次使用安罗替尼治疗，肿瘤再次缩小(疗效评价为SD)，目前仍然在维持治疗中。安罗替尼治疗的第1次无进展生存时间(PFS1)为15.5个月，第2次无进展生存时间(PFS2)为6.0+个月。这些病例显示，PD-1抑制剂可能逆转安罗替尼的获得性耐药，值得进一步研究。

    [关键词] PD-1抑制剂;安罗替尼;耐药性;特瑞普利;卡瑞利珠

    [Abstract] In this report， two patients with advanced oral adenocarcinoma progressed after chemotherapy and were switched to anlotinib. The tumors shrank(the efficacy evaluation was SD). Case 1 developed drug resistance 2.8 months after treatment with Anlotinib and the tumor progressed. The patient was given PD-1 inhibitor(treplimumab) for 1 cycle， and then treated with anlotinib again. The tumor shrank again(the efficacy evaluation was SD). The patient was still under maintenance treatment. The first progression-free survival time(PFS1) of anlotinib treatment was 2.8 months ......